Showing results (101-110 of 164) with videos related to

Sort By:
Pageof 17
Lung Cancer (Amsterdam, Netherlands)|March 1, 2023
Copy number variations mediate major pathological response to induction chemo-immunotherapy in unresectable stage IIIA-IIIB lung cancerLiang Zeng, Yuling Zhou, Xiangyu Zhang, et al.
Microbiology Spectrum|November 17, 2021
Alterations of the Human Lung and Gut Microbiomes in Non-Small Cell Lung Carcinomas and Distant MetastasisHui Lu, Na L Gao, Fan Tong, et al.
Nature Reviews. Clinical Oncology|November 11, 2025
Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC - mechanisms and evolving treatment approachesJing Zhao, Wanting Xu, Fei Zhou, et al.
European Journal of Cancer (Oxford, England : 1990)|November 10, 2020
Clinical impact of uncommon epidermal growth factor receptor exon 19 insertion-deletion variants on epidermal growth factor receptor-tyrosine kinase inhibitor efficacy in non-small-cell lung cancerXingzhou Peng, Xiaoyan Long, Li Liu, et al.
Lung Cancer (Amsterdam, Netherlands)|September 5, 2020
Characterization of MET exon 14 alteration and association with clinical outcomes of crizotinib in Chinese lung cancersHaiyan Yang, Zhen Zhou, Li Lin, et al.
Expert Review of Respiratory Medicine|September 30, 2023
Stratification of patients with KRAS-mutated advanced non-small cell lung cancer: improving prognosticsYuda Zhang, Fanxu Zeng, Shixuan Peng, et al.
Therapeutic Advances in Medical Oncology|November 24, 2022
Immune checkpoint inhibitors plus chemotherapy in patients with locally advanced or metastatic pulmonary sarcomatoid carcinoma: a multicentric real-world studyFei Zhou, Haoyue Guo, Xiaolong Zhou, et al.
NPJ Precision Oncology|February 5, 2026
Comparative analysis of ctDNA monitoring strategies in advanced NSCLC with MET exon 14 skipping mutations treated with ensartinibMo Zhou, Yin Zhu, Xuqi Sun, et al.
Clinical Lung Cancer|August 9, 2025
Clinical Outcomes of Patients With Advanced ALK-Rearranged Lung Squamous Cell Carcinoma Treated With ALK Tyrosine Kinase InhibitorsYuanze Sun, Dan Yang, Zhe Huang, et al.
BMC Cancer|May 15, 2023
Clinical activity of pembrolizumab with or without chemotherapy in advanced pulmonary large-cell and large-cell neuroendocrine carcinomas: a multicenter retrospective cohort studyLianxi Song, Fei Zhou, Tian Xu, et al.
Pageof 17